Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $788.00, giving the company a market capitalization of 82.45B. It carries a P/E multiple of 18.78 and pays a dividend yield of 33.6%.
On 2025-11-28, Regeneron(REGN) stock moved within a range of $777.00 to $797.73. With shares now at $788.00, the stock is trading +1.4% above its intraday low and -1.2% below the session's peak.
Trading activity shows a volume of 871.66K, compared to an average daily volume of 1.37M.
The stock's 52-week range extends from a low of $476.49 to a high of $800.99.
The stock's 52-week range extends from a low of $476.49 to a high of $800.99.
REGN News
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...
Regeneron (REGN) and Sanofi (SNY) announced that the European Commission has approved Dupixent for the treatment of moderate-to-severe chronic spontaneous urtic...
(RTTNews) - Sanofi (SNY, SNYNF, SAN.PA) and Regeneron Pharmaceuticals Inc. (REGN) announced that the European Commission has approved Dupixent (dupilumab) as a...
Analyst ratings
70%
of 30 ratingsMore REGN News
How bad were things for the S&P 500 Index ($SPX) on Thursday, Nov. 20? Not quite as bad as you might think. I’ve been writing here on Barchart for months, lame...
In recent trading, shares of Regeneron Pharmaceuticals, Inc. (Symbol: REGN) have crossed above the average analyst 12-month target price of $696.42, changing ha...
Regeneron Pharmaceuticals (REGN) just received FDA approval for its Eylea HD 8 mg injection to treat macular edema following retinal vein occlusion. This approv...
On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said he prefers Netflix, Inc. (NASDAQ:NFLX) over fuboTV Inc. (NYSE:FUBO) . FuboTV reported earni...
